#MCAW2020: Building the evidence base with Drug Science

Tuesday 3rd November 12.30 - 1.15pm

 
ds
 

Research is key to evidencing the safety & efficacy of medical cannabis, in order to enable access for all patients who could benefit.

Join the Drug Science team to discuss research to improve understanding of medical cannabis. Drug Science’s Project Twenty21 aims to monitor the health outcomes of 20,000 UK patients using cannabis based medicinal products.

Panel

Professor David Nutt - founding Chair of Drug Science, psychiatrist & Edmund J. Safra Professor of Neuropsychopharmacology in Imperial College London

Dr Anne Schlag - Head of Research at Drug Science and Honorary Fellow at Imperial College London.

David Badcock - Drug Science CEO

Amelia Middlemiss - Project Twenty21 Director

Suzy Gage - Project Twenty21 Patient Liaison

Lucy Stafford - Advocacy Director at PLEA

Register for free below

Medical Cannabis Awareness Week logo

During Medical Cannabis Awareness Week 2020, PLEA is collaborating with patients, doctors, colleagues and organisations from across the sector, friends and allies to share our plea, using the hashtag #MCAW2020.

Previous
Previous

#MCAW2020: Is there a role for cannabis in palliative care? with Dr Claude Cyr

Next
Next

#MCAW2020: Medical cannabis in paediatric care with Dr Evan Lewis